Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01NDN
|
||||
| Former ID |
DIB015287
|
||||
| Drug Name |
SNG-8006
|
||||
| Synonyms |
Estrogen receptor alpha-36 antagonist (osteoporosis), Shenogen Pharma
|
||||
| Indication | Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] | Investigative | [543898] | ||
| Company |
Shenogen Pharma Group Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Antagonist | [543898] | |
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.